I'm a paragraph. Click here to add your own text​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Our publications

In order to grow and develop as people, as professionals, and as a company, we find it essential to contribute to the academic progress. Below we provide links to posters and publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.


Brekkan A., Lopez-Lazaro L., Plan EL., Nyberg J., Kankanwadi S., Karlsson MO., Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies. AAPS J. 2019 Jul 8;21(5):85.

Nyberg J., Jonsson EN., Karlsson MO., Häggström J., members of the HBGDki Community., Properties of the full random effect modelling approach with missing covariates. (2019) Preprint, doi: https://doi.org/10.1101/656470

Heimbach T., Suarez-Sharp S., Kakhi M., Holmstock N., Olivares-Morales A., Pepin X., Sjögren E., Tsakalozou E., Seo P., Li M., Zhang X., Lin HP., Montague T., Mitra A., Morris D., Patel N., Kesisoglou F., Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report. (2019) AAPS J. 2019 Feb 11;21(2):29.

Netterberg I., Li CC., Molinero L., Budha N., Sukumaran S., Stroh M., Jonsson EN., Friberg LE., A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. (2019) Clin Pharmacol Ther. 2019 Feb;105(2):486-495.


Guiastrennec B., Sonne DP., Bergstrand M., Vilsbøll T., Knop FK., Karlsson MO., Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. (2019) CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):603-612.

Terranova N., Smith MK., Nordgren R., Comets E., Lavielle M., Harling K., Hooker AC., Sarr C., Mentré F., Yvon F., Swat MJ., The Standard Output: A Tool-Agnostic Modeling Storage Format. (2018) CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):543-546.

Suarez-Sharp S., Cohen M., Kesisoglou F., Abend A., Marroum P., Delvadia P., Kotzagiorgis E., Li M., Nordmark A., Bandi N., Sjögren E., Babiskin A., Heimbach T., Kijima S., Mandula H., Raines K., Seo P., Zhang X. Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report. (2018) AAPS J. 2018 Aug 27;20(6):93.

Brekkan A., Lopez-Lazaro L., Yngman G., Plan EL.Acharya C., Hooker AC.,Kankanwadi S., Karlsson MO., A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim. (2018) AAPS J. 2018 Aug 15;20(5):91

Rasmussen CH., Smith MK., Ito K., Sundararajan V., Magnusson MO., Jonsson NE., Fostvedt L., Burger P., McFadyen L., Tensfeldt TG., Nicholas T., PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow. (2018) AAPS J. 2018 Mar 16;20(3):52


Friberg Hietala S., Manolis E., Musuamba F. T., (2017) A Regulatory View on Dose Finding Studies and on the Value of Dose-Exposure-Response Analysis. In O’Quigley J., Iasonos A., Bornkamp B., (Eds.), Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Boca Raton FL:CRC Press

Magnusson M. O.Samtani M. N. Plan E. L., Jonsson E. N.Rossenu S., Vermeulen A., Russu A. Dosing and Switching Strategies for Paliperidone Palmitate 3-MonthFormulation in Patients with Schizophrenia Based on Population PharmacokineticModeling and Simulation, and Clinical Trial Data. (2017) CNS Drugs.

Dosne AG., Bergstrand M., Karlsson M. O., An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty. (2017) Clin. Pharmacol. Ther., 101: S5–S99

Conrado DJ., Karlsson MO., Romero K., Sarr C., Wilkins JJ., Open innovation: Towards sharing of data, models and workflows. (2017) Eur J Pharm Sci. 2017 Nov 15;109S:S65-S71

Röshammar D., Bergstrand M., Andersson T., Storey R.F., Hamrén B. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
. (2017) Int J Clin Pharmacol Ther. Jan 30.

Nguyen T., Mouksassi M.-S., Holford N., Al-Huniti N., Freedman I., Hooker A., John J., Karlsson M., Mould D., Pérez Ruixo J., Plan E. L., Savic R., van Hasselt J., Weber B., Zhou C., Comets E., Mentré F. for the Model Evaluation Group of the International Society of Pharmacometrics (ISoP) Best Practice Committee, Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. (2017) CPT Pharmacometrics Syst. Pharmacol.


Slejko JF., Willke RJ., Ribbing J., Milligan., Translating Pharmacometrics to a Pharmacoeconomic Model of COPD. (2016) Value Health. 2016 Dec;19(8):1026-1032

Röshammar D., Nyberg J., Andersson T., Stanski D., Storey R. F., Hamrén B. Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. (2016) J Clin Pharmacol. Nov.

Magnusson M. O., Samtani M.N., Plan E.L., Jonsson E. N., Rossenu S., Vermeulen A., Russu A. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. (2016) Clin Pharmacokinet., 56: 421

van Schaick E., Benninga M. A., Levine A., Magnusson M. O., Troy S., Development of apopulation pharmacokinetic model of prucalopride in children with functionalconstipation. (2016) Pharma Res Per, 4(4), e00236. 

Magnusson M. O. Application of a multi-criteria decision analysis model in the dose selection of combination therapy for overactive bladder. (2016) WCoP, Talk: Symposium 5, Pharmacometric approaches to optimize dose selection Abstr 125.

Jonsson E. N., Xie R., Marshall S. F., Arends R. H. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain. (2016) Br J Clin Pharmacol. Apr;81(4):688-99

Jonsson E. N., Nyberg J., Häggström J., Lifecycle Auxology & Neurocognitive Development team, representing the Healthy Birth, Growth and Development knowledge integration (HBGDki) community. Determinants for physical growth patterns in low- and middle-income countries. (2016) PAGE 25 Abstr 5844, Talk: Growth.

Magnusson M. O., Plan E. L., Remy A., König M., Aigner S., Braun, V., Zipp D., Zhou X., Wolter R., Schüttrumpf J., Wartenberg-Demand A., Dälken B., Rharbaoui F. Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis. (2016) PAGE 25 Abstr 5708.


Hamberg AK., Hellman J., Dahlberg J., Jonsson E. N., Wadelius M. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. (2015) BMC Med Inform Decis Mak. Feb 7;15:7

Khariton T., Jonsson E. N., Bergstrand M., Carrothers T. J., Ghahramani P. Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD). (2015) J Pharmacokinet Pharmacodyn 42(Suppl 1): 11

Khariton T., Jonsson E. N., Bergstrand M., Carrothers T. J., Ghahramani P. PKPD Modeling of Vilazodone (VLZ) in Adult Patients with Generalized Anxiety Disorder (GAD). (2015) J Pharmacokinet Pharmacodyn 42(Suppl 1): 11

Magnusson M. O., Samtani M. N., Plan E. L., Jonsson E. N., Rossenu S., Vermeulen A. Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations. (2015) PAGE 24 Abstr 3643.

Magnusson M. O., Samtani M. N., Plan E. L., Jonsson E. N., Rossenu S., Vermeulen A. Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation. (2015) PAGE 24 Abstr 3408.


Plan E. L. Modeling and simulation of count data. (2014) CPT Pharmacometrics Syst.Pharmacol. 3, e129.

Khariton T., Bergstrand M., Plan E. L., Ghahramani P. A Population PKPD Model for Changes in Sexual Function Questionnaire (CSFQ) in Patients with Major Depressive Disorder (MDD) Treated with Vilazodone or Placebo. (2014)  J Pharmacokinet Pharmacodyn 41(Suppl 1): 7

Hamberg A. K., Wadelius M., Friberg L. E., Biss T. T., Kamali F., Jonsson E. N. Characterizing variability in warfarin dose requirements in children using modelling and simulation. (2014) Br J Clin Pharmacol. Jul;78(1):158-69

Magnusson M. O., Jonsson E. N., Chen C. L., Carrothers T., Ghahramani P. A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy. (2014) PAGE 23 Abstr 3162.

Jonsson E. N., Magnusson M. O., Chen C. L., Carrothers T., Ghahramani P. A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy. (2014) PAGE 23 Abstr 3150.


Justin J. Wilkins J. J., Jonsson E. N. Reproducible Pharmacometrics.  (2013) PAGE 22 Abstr 2774 Oral: Tutorial